Virax Biolabs Group Ltd SEC filings VRAX
Virax Biolabs Group Ltd has 159 filings in SEC EDGAR's recent list, going back to Dec 27, 2021. Its latest annual report, Form 20-F, was filed on Jul 6, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Sep 10, 2026 | — |
| 424B5 | Prospectus supplement | Sep 4, 2026 | — |
| F-3/A | Filing | Sep 2, 2026 | — |
| F-3 | Shelf registration (foreign issuer) | Jul 24, 2026 | — |
| 424B3 | Prospectus | Dec 31, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 18, 2025 | — |
| S-8 | Employee stock plan registration | Jan 30, 2025 | — |
| 424B5 | Prospectus supplement | Sep 30, 2024 | — |
| 424B5 | Prospectus supplement | Aug 23, 2024 | — |
| 424B5 | Prospectus supplement | Jan 22, 2024 | — |
| 424B3 | Prospectus | Dec 20, 2023 | — |
| 424B3 | Prospectus | Dec 20, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | Dec 5, 2023 | — |
| 424B3 | Prospectus | Mar 31, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Mar 22, 2023 | — |
| 424B3 | Prospectus | Dec 2, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Nov 21, 2022 | — |
| 424B4 | Prospectus | Jul 21, 2022 | — |
| FWP | Free writing prospectus | Jul 1, 2022 | — |
| FWP | Free writing prospectus | Jun 30, 2022 | — |
| F-1/A | Registration statement | Jun 27, 2022 | — |
| F-1/A | Registration statement | Jun 24, 2022 | — |
| F-1/A | Amendment no. 4 to form f-1 | Jun 21, 2022 | — |
| F-1/A | Registration statement | Jun 7, 2022 | — |
| F-1/A | Registration statement | May 11, 2022 | — |
| F-1/A | Registration statement | Apr 25, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Mar 18, 2022 | — |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.